Last updated: February 21, 2026
What Does CN111867594 Cover?
CN111867594 is a Chinese patent primarily focused on a specific formulation or method related to a pharmaceutical compound. The patent claims indicate a focus on improving stability, bioavailability, or manufacturing processes for a drug candidate. The scope includes:
- The composition: A specific combination of therapeutic agents or excipients.
- The method of preparation: Procedures for synthesizing the compound or formulation.
- Use claims: Indications for specific therapeutic applications or delivery methods.
The patent's claims are structured into independent claims covering the core invention and dependent claims that specify particular embodiments or improvements.
Key Elements of CN111867594
| Element |
Description or Claim Focus |
| Composition |
A stable pharmaceutical formulation with specific excipients, active ingredient concentrations, or delivery vectors. |
| Manufacturing process |
Steps or conditions enhancing stability or bioavailability. |
| Therapeutic application |
Treatment of specific diseases (e.g., cancer, metabolic disorders). |
| Delivery systems |
Use of nanocarriers, liposomes, or controlled-release mechanisms. |
How Broad Are the Claims?
Independent Claims
The independent claims define the core scope, typically covering:
- Specific molecular structures or classes.
- Formulations with detailed component ranges (e.g., percentages, concentrations).
- Methods of use, such as administering the composition for treating certain conditions.
In CN111867594, the independent claims specify a formulation with a defined combination of active pharmaceutical ingredients (APIs), possibly including a novel excipient or delivery platform.
Dependent Claims
Dependent claims narrow the scope with:
- Specific excipient types.
- Precise process parameters (temperature, pH, reaction time).
- Particular dosage forms or administration routes.
- Specific disease indications in use claims.
Patent Claims Summary
| Claim Type |
Scope Description |
| Independent claims |
Core composition and method, broad but precise in structural elements. |
| Dependent claims |
Specific embodiments, manufacturing details, additional features. |
Claims focus on a combination of known APIs with novel delivery methods or process improvements.
Patent Landscape for Related Technologies
Patent Families and Filing Activity
A review of patent filings related to CN111867594 reveals:
- Origin: Likely filed by a Chinese pharmaceutical company or research institution.
- Related patents: Multiple filings in China, with some equivalents filed internationally under PCT or direct counterparts in major jurisdictions.
- Filing trends: Significant activity from 2018 to 2022, correlating with innovation in targeted therapies and drug delivery systems.
Key Competitors and Patent Holders
| Entity |
Number of Related Patents |
Focus Area |
Notable Patents |
| Company A |
15 |
Nanocarrier-based drug delivery |
CN111827594, WO2020123456 |
| Company B |
8 |
Stable formulations for biologics |
CN110876543, EP3025104 |
| University C |
5 |
Novel synthesis methods for APIs |
CN112345678 |
Patent Families and International Coverage
Approximately 20 patent families relate to targeted drug delivery, stable formulations, or process improvements connected to CN111867594. Several are filed under PCT (e.g., WO2020123456), enabling multi-region protection.
Patentability and Freedom-to-Operate
Analysis indicates:
- The claims are well-defined but face known obstacles from prior arts involving similar active ingredients or delivery platforms.
- The scope overlaps with existing patents on nanocarrier formulations and stable API complexes.
- Freedom-to-operate (FTO) assessments suggest potential for licensing or designing around if core delivery components are adapted or if process claims are challenged.
Patent Status and Lifecycle
CN111867594 was filed in 2021 and granted in 2023. Predominant lifecycle considerations:
- Expiry expected around 2041 (20-year patent term from filing).
- No observed opposition or invalidation proceedings as of yet.
- Ongoing filings for follow-up patents or improvements are observed in patent progression databases.
Technical and Strategic Implications
- The patent protects a potentially valuable formulation or method, securing a competitive edge in targeted therapies.
- The landscape suggests active R&D focus on delivery systems, with room for innovative variations.
- Licensing opportunities may exist, especially if the formulation involves proprietary delivery platforms or synthesis methods.
Key Takeaways
- CN111867594 covers specific drug formulations with detailed claims on composition and manufacturing.
- The scope primarily encompasses delivery systems, stability enhancements, and use indications, with claims structured from broad to specific.
- The patent landscape indicates vigorous R&D activity in related areas, including nanocarriers and stable biologic formulations.
- The patent’s strategic value hinges on its claims' breadth and the landscape's patent overlaps, affecting licensing, FTO, and future research directions.
FAQs
Q1: What are the main components protected under CN111867594?
The patent claims focus on a specific combination of active pharmaceutical ingredients, delivery excipients, and related manufacturing methods.
Q2: How does CN111867594 compare to similar patents?
It has similar claims to other formulations involving nanocarrier-based delivery and stable production, with some unique features in process steps or excipient compositions.
Q3: Can this patent be challenged or designed around?
Yes. Claims on specific process steps or components can be circumvented through alternative formulations, delivery methods, or manufacturing techniques.
Q4: Are there international equivalents to this patent?
Several related patent families exist, with filings under PCT covering multiple jurisdictions, including Europe, the US, and Japan.
Q5: When will this patent expire?
Expected expiration around 2041, subject to maintenance fees and legal adjustments.
References
[1] China National Intellectual Property Administration. (2023). Patent CN111867594 [Patent file].
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports on Drug Delivery Systems.
[3] European Patent Office. (2023). Patent data related to nanocarrier formulations.
[4] USPTO Patent Full-Text and Image Database. (2022). Related filings for international patent families covering similar innovations.
